Value assessment of oncology drugs using a weighted criterion‐based approach-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Value assessment of oncology drugs using a weighted criterion‐based approach

Published:2019-12-20 Issue:7 Volume:126 Page:1530-1540
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Ezeife Doreen A.¹^ORCID,Dionne Francois²,Fares Aline Fusco³,Cusano Ellen Laura Rose¹,Fazelzad Rouhi⁴,Ng Wenzie³,Husereau Don⁵,Ali Farzad⁶,Sit Christina⁷,Stein Barry⁸,Law Jennifer H.³,Le Lisa³,Ellis Peter Michael⁹,Berry Scott¹⁰,Peacock Stuart¹¹,Mitton Craig¹²,Earle Craig C.¹³,Chan Kelvin K. W.¹³^ORCID,Leighl Natasha B.³

Affiliation:

1. Department of Oncology Tom Baker Cancer Centre Calgary Alberta Canada

2. Prioritize Consulting Ltd Vancouver British Columbia Canada

3. Department of Medical Oncology and Hematology Princess Margaret Cancer Centre Toronto Ontario Canada

4. Department of Medical Oncology and Hematology Library and Information Services, Princess Margaret Cancer Centre Toronto Ontario Canada

5. School of Epidemiology and Public Health University of Ottawa Ottawa Ontario Canada

6. Pfizer Inc New York New York

7. Lung Cancer Canada Toronto Ontario Canada

8. Colorectal Cancer Canada Montreal Quebec Canada

9. Juravinski Cancer Centre Hamilton Ontario Canada

10. Cancer Centre of Southeastern Ontario Kingston Ontario Canada

11. British Columbia Cancer Agency Vancouver British Columbia Canada

12. The University of British Columbia Vancouver British Columbia Canada

13. Sunnybrook Odette Cancer Centre Toronto Ontario Canada

Funder

Canadian Institutes of Health Research

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32639

Reference35 articles.

1. The high price of anticancer drugs: origins, implications, barriers, solutions

2. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration

3. When Are "Positive" Clinical Trials in Oncology Truly Positive?

4. Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies

5. Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Narrative review of value frameworks in urothelial carcinoma and positioning of enfortumab vedotin;Journal of Medical Economics;2024-09-11

2. Development of a Value Assessment Framework for Pediatric Health Technologies Using Multicriteria Decision Analysis: Expanding the Value Lens for Funding Decision Making;Value in Health;2024-07

3. A Step Toward the Development of the First National Multi-Criteria Decision Analysis Framework to Support Healthcare Decision Making in Saudi Arabia;Value in Health Regional Issues;2024-05

4. Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration;Current Oncology;2024-04-01

5. Value elements and methods of value-based pricing for drugs in Japan: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2023-06-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3